Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Cetuximab in Advanced Solid Tumors
NCT02020577Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of afatinib in solid tumor (advanced stage), squamous cell carcinoma of the lung (LSCC) and squamous cell carcinoma of the head and neck (HNSCC), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose of Afatinib at 21 days, Dose Limiting Toxicities at 21 days and 1 more. Started Dec 2013; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the lung (LSCC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02020577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020577.